Health Condition 1: C50- Malignant neoplasm of breast
Conditions
Interventions
Intervention1: Topical Zinc Sulfate:
The dispersible zinc sulphate tablet 50 mg will be reconstituted in distilled water (50 mg in 10 ml)
Control Intervention1: NA: NA
Sponsors
Dr Mirunalini R
Eligibility
Inclusion criteria
Inclusion criteria: patients with breast cancer planned for curative intent therapy (neoadjuvant or adjuvant ) with epirubicin and cyclophosphamide agents during first cycle
Exclusion criteria
Exclusion criteria: 1. Patients who had received zinc preparations within the last two weeks of enrolment 2. Known hypersensitivity to the drug 3. Known psychiatric disorder 4. Regular alcohol intake (3 or more drinks equivalent of 45 ml of liquor per week)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in taste perception by taste acuity method Change in CiTAS scoreTimepoint: Baseline and two weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse drug reaction to Topical ZincTimepoint: Over two weeks | — |
Countries
India
Contacts
Public ContactMirunalini R
JIPMER, Puducherry
Outcome results
None listed